Idorsia Ltd. (IDRSF)
7.25
0.00 (0.00%)
USD |
OTCM |
Aug 24, 16:00
Idorsia Total Liabilities (Quarterly) : 2.055B for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.055B |
| March 31, 2026 | 2.062B |
| December 31, 2025 | 2.023B |
| September 30, 2025 | 1.999B |
| June 30, 2025 | 2.060B |
| March 31, 2025 | 1.795B |
| December 31, 2024 | 1.896B |
| September 30, 2024 | 1.639B |
| June 30, 2024 | 1.906B |
| March 31, 2024 | 1.907B |
| December 31, 2023 | 1.745B |
| September 30, 2023 | 1.622B |
| June 30, 2023 | 1.753B |
| March 31, 2023 | 1.706B |
| December 31, 2022 | 1.692B |
| September 30, 2022 | 1.593B |
| June 30, 2022 | 1.458B |
| March 31, 2022 | 1.497B |
| December 31, 2021 | 1.513B |
| Date | Value |
|---|---|
| September 30, 2021 | 1.555B |
| June 30, 2021 | 893.03M |
| March 31, 2021 | 859.61M |
| December 31, 2020 | 961.46M |
| September 30, 2020 | 913.07M |
| June 30, 2020 | 885.06M |
| March 31, 2020 | 860.08M |
| December 31, 2019 | 867.30M |
| September 30, 2019 | 809.88M |
| June 30, 2019 | 846.55M |
| March 31, 2019 | 808.50M |
| December 31, 2018 | 759.94M |
| September 30, 2018 | 775.59M |
| June 30, 2018 | 545.78M |
| March 31, 2018 | 559.70M |
| December 31, 2017 | 566.82M |
| September 30, 2017 | 475.74M |
| June 30, 2017 | 469.00M |
| March 31, 2017 | 411.65M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 3.973B |
| AC Immune SA | 142.85M |
| CRISPR Therapeutics AG | 904.22M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 575.13M |
| Shareholders Equity (Quarterly) | -1.480B |
| Debt to Equity Ratio | -1.124 |
| Current Ratio | 0.5819 |
| Net Debt Paydown Yield | -2.55% |